Clarkston Capital Partners LLC Raises Position in IQVIA Holdings Inc. (NYSE:IQV)

Clarkston Capital Partners LLC grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 60.0% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 24,000 shares of the medical research company’s stock after purchasing an additional 9,000 shares during the period. Clarkston Capital Partners LLC’s holdings in IQVIA were worth $4,716,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Smith Group Asset Management LLC bought a new stake in shares of IQVIA in the 4th quarter worth $1,616,000. Nordea Investment Management AB boosted its position in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after buying an additional 452,029 shares during the last quarter. Hickory Asset Management Inc. bought a new stake in IQVIA in the 4th quarter worth about $941,000. Fifth Third Bancorp raised its position in IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after buying an additional 1,521 shares during the last quarter. Finally, Graphene Investments SAS boosted its holdings in shares of IQVIA by 22.0% during the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock valued at $2,948,000 after acquiring an additional 2,700 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 7.8 %

Shares of IQV stock opened at $154.63 on Friday. The company has a market capitalization of $27.26 billion, a price-to-earnings ratio of 20.62, a PEG ratio of 1.99 and a beta of 1.46. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company’s fifty day moving average price is $189.67 and its 200-day moving average price is $203.82. IQVIA Holdings Inc. has a one year low of $154.35 and a one year high of $252.88.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the topic of a number of research analyst reports. Barclays lowered their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Stifel Nicolaus lowered their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. Finally, Morgan Stanley upped their price target on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.